Literature DB >> 15333577

Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen.

Pascal Maurice1, Chantal Legrand, Françoise Fauvel-Lafeve.   

Abstract

Platelet adhesion to vascular collagens is an essential step in the initiation of hemostasis and thrombosis. Several platelet receptors interact with type I and type III collagens, including GP Ia/IIa and GP VI. We recently described a new platelet receptor (TIIICBP) specific for a type III collagen-related primary binding sequence, the KOGEOGPK octapeptide. Here, we characterize platelet adhesion to the immobilized octapeptide and demonstrate that this adhesion 1) is Ca2+ and Mg2+ independent, suggesting a noninvolvement of GP Ia/IIa; 2) is not inhibited by an antibody against GP VI; and 3) triggers platelet protein tyrosine phosphorylation. Whereas TXA2 has minimal effects, released ADP via only P2Y12 potentiates platelet adhesion to the octapeptide. Octapeptide-induced platelet adhesion triggers platelet signaling through tyrosine phosphorylation of the 68 kDa subunit of TIIICBP, Syk, PLCgamma2, and FAK. Tyrosine phosphorylation of the FcR gamma-chain and LAT is also observed but to a lesser extent than with type III collagen, suggesting the requirement of GP VI for full tyrosine phosphorylation of FcR gamma-chain and LAT. The present study provides evidence for a critical role for the type III collagen-related KOGEOGPK octapeptide in mediating platelet adhesion and signaling, and consequently in platelet-collagen interactions.-

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15333577     DOI: 10.1096/fj.03-1151com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

1.  The platelet receptor for type III collagen (TIIICBP) is present in platelet membrane lipid microdomains (rafts).

Authors:  Pascal Maurice; Ludovic Waeckel; Viviane Pires; Pascal Sonnet; Monique Lemesle; Brigitte Arbeille; Jany Vassy; Jacques Rochette; Chantal Legrand; Françoise Fauvel-Lafève
Journal:  Histochem Cell Biol       Date:  2005-10-05       Impact factor: 4.304

2.  Inhibition of Arginine Methylation Impairs Platelet Function.

Authors:  Alistair James Marsden; David R J Riley; Antonia Barry; Jawad S Khalil; Barbara-Ann Guinn; Neil T Kemp; Francisco Rivero; Pedro Beltran-Alvarez
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-09

3.  Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization.

Authors:  M C Chang; B J Uang; C Y Tsai; H L Wu; B R Lin; C S Lee; Y J Chen; C H Chang; Y L Tsai; C J Kao; J H Jeng
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

4.  Molecular underpinnings of integrin binding to collagen-mimetic peptides containing vascular Ehlers-Danlos syndrome-associated substitutions.

Authors:  Cody L Hoop; Allysa P Kemraj; Baifan Wang; Sonal Gahlawat; Madison Godesky; Jie Zhu; Haley R Warren; David A Case; David I Shreiber; Jean Baum
Journal:  J Biol Chem       Date:  2019-08-12       Impact factor: 5.157

5.  The collαgen III fibril has a "flexi-rod" structure of flexible sequences interspersed with rigid bioactive domains including two with hemostatic roles.

Authors:  J Des Parkin; James D San Antonio; Anton V Persikov; Hayat Dagher; Raymond Dalgleish; Shane T Jensen; Xavier Jeunemaitre; Judy Savige
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

Review 6.  Platelet thrombin receptor antagonism and atherothrombosis.

Authors:  Dominick J Angiolillo; Davide Capodanno; Shinya Goto
Journal:  Eur Heart J       Date:  2009-11-30       Impact factor: 29.983

7.  Propolis Modifies Collagen Types I and III Accumulation in the Matrix of Burnt Tissue.

Authors:  Pawel Olczyk; Grzegorz Wisowski; Katarzyna Komosinska-Vassev; Jerzy Stojko; Katarzyna Klimek; Monika Olczyk; Ewa M Kozma
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-28       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.